Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.940 -0.010 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Iovance Biotherapeutics Stock Is Surging: Here's Why
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
 
Via Benzinga
Recap: Iovance Biotherapeutics Q3 Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings for Iovance Biotherapeutics
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: 
Via Benzinga
Why Iovance Biotherapeutics Is Crashing Today
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy. 
Via The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
7 Analysts Have This to Say About Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Preview: Iovance Biotherapeutics's Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
5 Top Stocks Cathie Wood Is Selling This Week
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Iovance Biotherapeutics: Q2 Earnings Insights
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.